We also observed that patients who obtained a less than 50% reduction in MMD during treatment with CGRP (pathway) mAbs did not show a relevant increase in MMD, MHD, and AMD during the mandatory treatment break. The gene discussed is CALCA; the disease is age-related macular degeneration.